Successful rapid desensitization to the antibody-drug conjugate brentuximab vedotin in a patient with refractory Hodgkin lymphoma

J Oncol Pharm Pract. 2016 Feb;22(1):188-92. doi: 10.1177/1078155214567164. Epub 2015 Jan 12.
No abstract available

Publication types

  • Case Reports
  • Editorial

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bleomycin / administration & dosage
  • Brentuximab Vedotin
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Hodgkin Disease / drug therapy
  • Hodgkin Disease / immunology*
  • Humans
  • Immunoconjugates / immunology*
  • Ki-1 Antigen / immunology
  • Male
  • Prednisone / administration & dosage
  • Procarbazine / administration & dosage
  • Vincristine / administration & dosage

Substances

  • Immunoconjugates
  • Ki-1 Antigen
  • Bleomycin
  • Procarbazine
  • Vincristine
  • Etoposide
  • Brentuximab Vedotin
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • BEACOPP protocol